Oncogene-Expressing Senescent Melanocytes Up-Regulate MHC Class II, a Candidate Melanoma Suppressor Function

Area of Science:

• Immunology
• Oncology
• Cell Biology

Background:

• Oncogene-induced senescence (OIS) is a tumor suppressive mechanism involving cell cycle arrest and secretion of inflammatory factors.
• The interaction between OIS cells and the immune system, particularly in melanoma, remains incompletely understood.
• Melanoma driver mutations like NRASQ61K and BRAFV600E can induce OIS in primary human melanocytes.

Purpose of the Study:

• To investigate the immune interactions of OIS melanocytes.
• To determine if OIS in melanocytes affects antigen presentation.
• To explore the therapeutic implications of OIS-mediated immune responses in melanoma.

Main Methods:

• Induction of OIS in primary human melanocytes using melanoma driver mutations (NRASQ61K, BRAFV600E).
• Analysis of major histocompatibility class II (MHC-II) expression and its regulatory pathways (IL-1ß, CIITA).
• In vitro assessment of T-cell proliferation and in vivo studies of melanocyte migration and immune cell activation in mouse models.
• Correlation of MHC-II expression with patient outcomes in melanoma.

Main Results:

• OIS in melanocytes, driven by NRASQ61K and BRAFV600E, induces MHC-II expression via IL-1ß signaling and CIITA.
• OIS melanocytes activate T-cell proliferation in vitro.
• In vivo, oncogene-expressing melanocytes migrate to lymph nodes, promoting T-cell proliferation and an antigen presentation gene signature.

Conclusions:

• OIS in melanocytes is associated with an antigen presentation phenotype.
• This OIS-driven immune activation likely contributes to tumor suppression by engaging the adaptive immune system.
• MHC-II expression in melanoma patients correlates with favorable outcomes, supporting the role of OIS-mediated immunity.